NASDAQ Shariah screener · October 2026

Is Gilead Sciences, Inc. (GILD) Halal?

PASS

Gilead Sciences, Inc. · NASDAQ: GILD · Healthcare

The short answer

Yes — Gilead Sciences (GILD) passes this Shariah stock screen. The Foster City, California biopharmaceutical company sells medicines only — HIV ($20.8B of FY2025 sales, led by Biktarvy at $14.3B), liver disease, Veklury and oncology (Trodelvy, Yescarta, Tecartus) — with no haram business lines in its 10-K. Debt of $24,936M is about 13.62% of its ~$183.11B market cap (1,241,420,528 shares × $147.50, October 1, 2026), below the ~33% ceiling, and FY2025 interest income of $349M is about 1.19% of revenue ($29,443M), below the 5% ceiling. Debt rose in the first half of 2026 (net ~$1.3B of new issuance to help fund the ~$7.8B Arcellx acquisition), but the gate still passes comfortably. This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

Gate 1 — Business activity: PASS

Gilead Sciences, Inc. (NASDAQ: GILD), headquartered in Foster City, California, is a biopharmaceutical company operating in more than 35 countries, focused on discovering, developing and commercializing medicines for HIV, viral hepatitis, COVID-19 and cancer — it reports a single operating segment. FY2025 product sales were $28,915M: HIV $20,752M (~70% of revenue; Biktarvy alone $14,334M, plus Descovy $2,758M, Genvoya $1,498M, Odefsey $1,167M), Liver Disease $3,217M (Epclusa, Harvoni, Vemlidy, Livdelzi), Veklury (remdesivir) $911M, Oncology $3,236M (Trodelvy $1,397M; cell therapy Yescarta $1,495M + Tecartus $344M via Kite), and Other $799M; royalty, contract and other revenues $527M for total revenues of $29,443M. Business-screen implication (factual): the product lines are medicines and no haram-line revenue (alcohol, gambling, weapons, conventional finance) appears in the 10-K. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Per Gilead's FY2025 10-K (filed February 24, 2026; SEC CIK 882095), total interest-bearing debt was $24,936M — current portion of long-term debt, net $2,807M + long-term debt, net $22,129M. Against a market cap of about $183.11B (1,241,420,528 shares outstanding × $147.50, October 1, 2026), debt ÷ market cap is about 13.62% — below the ~33% ceiling. Cash, cash equivalents and marketable debt securities of $10,606M ($7,564M + $68M + $2,974M) are about 5.79% of market cap. Note: debt rose in H1 2026 — the company issued ~$4.1B of new debt (net of $2.8B repayments) to help fund the ~$7.8B Arcellx acquisition (closed April 28, 2026); Q2 2026 long-term debt was ~$23.8B per the 10-Q — the gate still passes comfortably. Facts only.

Gate 3 — Non-compliant income: PASS

Gilead's FY2025 10-K reports interest income of $349M against FY2025 revenue of $29,443M — about 1.19% of revenue, below the 5% non-compliant income ceiling. (The broader "Other (income) expense, net" line was $(798)M, including a $451M net gain from equity securities — a fair-value gain, not interest income — and is not part of this gate.) The income gate passes. Facts only.

Key figures used

Business: Gilead Sciences, Foster City, California — biopharmaceutical, single operating segment, 35+ countries; HIV (~70% of revenue), liver disease (HBV/HCV/HDV), Veklury (COVID-19), oncology (Trodelvy; Yescarta + Tecartus via Kite cell therapy)
FY2025 revenue $29,443M: HIV $20,752M (Biktarvy $14,334M, Descovy $2,758M, Genvoya $1,498M, Odefsey $1,167M), Liver Disease $3,217M, Veklury $911M, Oncology $3,236M, Other $799M, royalty/contract/other $527M
No haram business lines identified in the 10-K — Gate 1 passes
Debt: $24,936M (current portion of long-term debt $2,807M + long-term debt $22,129M, FY2025 10-K) — debt ÷ market cap ≈ 13.62% of ~$183.11B (1,241,420,528 shares × $147.50, Oct 1, 2026), under the ~33% ceiling
Cash: $10,606M (cash, cash equivalents $7,564M + marketable debt securities $68M short-term + $2,974M long-term) ≈ 5.79% of market cap
Interest income: $349M (FY2025 10-K Statements of Operations) vs FY2025 revenue $29,443M — ≈1.19% of revenue, under the 5% ceiling
H1 2026 context: net ~$1.3B new debt issued ($4.1B proceeds − $2.8B repayments) partly for the ~$7.8B Arcellx acquisition (closed Apr 28, 2026); cash fell to $3.2B — debt gate still passes comfortably
Musaffa: GILD covered, classified halal (Aug 2026); Zoya: inconclusive (contradictory page text); ShariaPortfolio: no entry

Frequently asked questions

What does Gilead do?

Gilead Sciences, Inc. (NASDAQ: GILD), headquartered in Foster City, California, is a biopharmaceutical company operating in more than 35 countries. It reports a single operating segment focused on discovering, developing and commercializing medicines for HIV, viral hepatitis (HBV/HCV/HDV), COVID-19 (Veklury) and oncology. FY2025 revenue was $29,443M: HIV $20,752M (~70%, led by Biktarvy at $14,334M), Liver Disease $3,217M, Veklury $911M, Oncology $3,236M (Trodelvy $1,397M; cell therapy Yescarta $1,495M + Tecartus $344M via its Kite unit), and royalty, contract and other revenues $527M.

Why does Gilead pass this Shariah stock screen?

All three gates pass. Gate 1 (business): Gilead's revenue comes from medicines — no alcohol, gambling, weapons or conventional-finance business lines appear in its 10-K. Gate 2 (debt): $24,936M of debt (current portion $2,807M + long-term $22,129M) is about 13.62% of its ~$183.11B market cap, below the ~33% ceiling. Gate 3 (non-compliant income): FY2025 interest income of $349M is about 1.19% of $29,443M revenue, below the 5% ceiling. Debt rose in H1 2026 (~$4.1B of new issuance, net of $2.8B repayments, partly for the ~$7.8B Arcellx acquisition), but the gate still passes comfortably. This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

What is Gilead's interest-bearing debt ratio?

Per Gilead's FY2025 10-K (filed February 24, 2026; SEC CIK 882095), total interest-bearing debt was $24,936M — current portion of long-term debt, net $2,807M plus long-term debt, net $22,129M. Against a market cap of about $183.11B (1,241,420,528 shares outstanding × $147.50, October 1, 2026), debt ÷ market cap is about 13.62% — below the ~33% ceiling. Cash, cash equivalents and marketable debt securities of $10,606M are about 5.79% of market cap. The debt gate passes; note that debt rose in H1 2026 (~$4.1B of new issuance, net of $2.8B repayments, partly for the ~$7.8B Arcellx acquisition closed April 28, 2026; Q2 2026 long-term debt ~$23.8B per the 10-Q). Facts only.

What is Gilead's non-compliant income ratio?

Gilead's FY2025 10-K (Consolidated Statements of Operations) reports interest income of $349M against FY2025 total revenue of $29,443M — about 1.19% of revenue, below the 5% non-compliant income ceiling. The broader "Other (income) expense, net" line of $(798)M includes a $451M net gain from equity securities (a fair-value gain, not interest income) and is not part of this gate. The income gate passes. Facts only.

Do Zoya, Musaffa, or ShariaPortfolio cover Gilead?

Musaffa covers Gilead: its GILD stock page classifies Gilead as halal under Musaffa's Shariah screening methodology (as of August 2026). Zoya's public GILD page renders contradictory auto-generated template text (simultaneously calling GILD Shariah-compliant and not compliant, and claiming $0 interest income against the 10-K's $349M), so no clean Zoya rating is retrievable without the app — honestly reported as inconclusive. ShariaPortfolio: no GILD entry found. This page applies the screen directly from Gilead's own filings.

Sources

Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).